Recent Updates
Recently added Catalysts
VSTM Positive Sentiment

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Wednesday, October 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Verastem Oncology has announced the appointment of Michael P. Bailey as the new President and CEO, effective January 1, 2027. This transition follows the planned retirement of Daniel Paterson, who has served as President and CEO. The move is seen as a strategic decision to ensure continuity in leadership.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Michael P. Bailey as new CEO is a strategic move.
  • Continuity in leadership with Bailey remaining on the Board.
  • Planned transition indicates stability and foresight in management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+143%
120-day peak, hindsight
Typical move
7.8%
average across 9 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
VS-7375
Phase 2 · Pancreatic Ductal Adenocarcinoma

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will also continue to serve on the Company’s Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and cont

Frequently Asked Questions

Who is the new CEO of Verastem Oncology?

Michael P. Bailey has been appointed as the new CEO.

When will the CEO transition take effect?

The transition will take effect on January 1, 2027.

Who is stepping down as CEO?

Daniel Paterson will step down as President and CEO.

Will Michael P. Bailey serve on the Board?

Yes, he will continue to serve on the Company's Board of Directors.

ShareAdd on Google
Tags: VSTM Verastem Oncology Michael P. Bailey Daniel Paterson CEO transition biopharmaceutical
Last updated: Oct 14, 2026

Biotech snapshot

Cash runway
$136M liquidity · $15M/mo burn
~7 mo
Medium dilution risk
Lead asset
VS-7375Phase 2
Pancreatic Ductal Adenocarcinoma →

Catalyst track record

+143%
best trade around VSTM's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for VSTM.

See every catalyst's timing & PoA →